Published in Clin Cancer Res on July 01, 2001
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer (2007) 1.61
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab (2010) 1.44
Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng (2010) 1.25
Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11
New paradigms for advanced prostate cancer. Rev Urol (2007) 1.09
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res (2010) 1.05
Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett (2009) 1.04
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer (2009) 1.01
VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol (2009) 0.99
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer (2003) 0.98
Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets (2012) 0.97
The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol (2006) 0.96
Current treatment strategies for castration-resistant prostate cancer. Korean J Urol (2011) 0.93
Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol (2005) 0.93
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol (2009) 0.93
Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov (2007) 0.92
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs (2002) 0.92
Anti-angiogenesis approach to genitourinary cancer treatment. Update Cancer Ther (2009) 0.92
Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos. Int J Nanomedicine (2011) 0.91
Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol (2010) 0.91
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2008) 0.90
Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology. Neoplasia (2005) 0.90
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol (2010) 0.87
Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol (2010) 0.87
Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology (2008) 0.87
Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother (2010) 0.86
From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res (2010) 0.84
Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. Eur Radiol (2008) 0.83
Thalidomide-a notorious sedative to a wonder anticancer drug. Curr Med Chem (2013) 0.83
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis (2011) 0.82
Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (2010) 0.80
Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Mol Cancer Ther (2015) 0.79
Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer (2010) 0.79
Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol (2007) 0.79
Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget (2015) 0.77
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer. Rev Urol (2003) 0.77
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol (2006) 0.77
Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. Invest New Drugs (2006) 0.76
Phase II trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer. Mol Clin Oncol (2015) 0.76
Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma. Korean J Intern Med (2010) 0.75
Prostate cancer: thalidomide for prostate cancer: is there progress? Nat Rev Urol (2009) 0.75
Novel therapies in genitourinary cancer: an update. J Hematol Oncol (2008) 0.75
New therapeutic targets in the treatment of prostate cancer. Indian J Urol (2007) 0.75
Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis. Immunology (2016) 0.75
Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101). Rev Urol (2007) 0.75
Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer. Cancers (Basel) (2011) 0.75
The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol (2004) 0.75
Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol (1967) 22.39
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Controlled trial of early mobilisation and discharge from hospital in uncomplicated myocardial infarction. Lancet (1971) 6.52
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
The contribution of lead-contaminated house dust and residential soil to children's blood lead levels. A pooled analysis of 12 epidemiologic studies. Environ Res (1998) 4.94
Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell (1994) 4.50
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Cost effectiveness of community leg ulcer clinics: randomised controlled trial. BMJ (1998) 4.10
Visceral abdominal-fat accumulation associated with use of indinavir. Lancet (1998) 4.05
Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet (1999) 4.04
Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev (2007) 4.02
A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry (1995) 3.89
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Assessment of the severity of primary depressive illness. Wakefield self-assessment depression inventory. Psychol Med (1971) 3.75
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci (1996) 3.49
HIV-1 drug resistance in newly infected individuals. JAMA (1999) 3.49
Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med (2000) 3.44
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet (2001) 3.26
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol (1990) 3.22
The Leeds scales for the self-assessment of anxiety and depression. Br J Psychiatry (1976) 3.15
Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch Dermatol (1999) 3.14
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology (1996) 2.90
Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol (2001) 2.82
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol (1995) 2.78
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol (1996) 2.67
Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol (1999) 2.67
Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (2000) 2.66
Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest (1999) 2.65
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol (1995) 2.59
A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg (1987) 2.54
How to optimize the drop plate method for enumerating bacteria. J Microbiol Methods (2001) 2.54
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med (1989) 2.46
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med (2001) 2.45
Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum (2000) 2.41
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
Rating depressive patients. J Clin Psychiatry (1980) 2.27
Neonatal sunburn and melanoma in mice. Nature (2001) 2.25
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
A citation analysis of the Bulletin of the Medical Library Association. Bull Med Libr Assoc (1977) 2.18
Backwardness of human neuroanatomy. Nature (1993) 2.18
Pre-injury neuro-psychiatric medication use, alone or in combination with cardiac medications, may affect outcomes in trauma patients. J Postgrad Med (2014) 2.16
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer (2009) 2.13
Magnetic resonance imaging of cerebral hemiatrophy. J Formos Med Assoc (1993) 2.10
Transdermally administered fentanyl for pain management. Clin Pharm (1992) 2.09
A survey of injection site lesions in fed cattle in Canada. Can Vet J (1997) 2.07
Predicting the arrhythmogenic foci of atrial fibrillation before atrial transseptal procedure: implication for catheter ablation. J Cardiovasc Electrophysiol (2000) 2.06
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
The association between Internet addiction and psychiatric disorder: a review of the literature. Eur Psychiatry (2011) 2.02
Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol (1995) 2.02
Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med (1997) 2.01
Current status of biomedical book reviewing. II. Time lag in biomedical book reviewing. Bull Med Libr Assoc (1974) 2.00
Applications of free living plant growth-promoting rhizobacteria. Antonie Van Leeuwenhoek (2004) 1.99
Counterpoint: test the value of hyperthermia in patients with carcinoma of the cervix being treated with concurrent chemotherapy and radiation. Int J Hyperthermia (2002) 1.98
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest (1994) 1.97
Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity. Arch Gen Psychiatry (1995) 1.97
Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol (1996) 1.95
The impact of disease severity on the informed consent process in clinical research. Am J Med (1996) 1.94
Eating disorders in Asian girls. Br J Psychiatry (1991) 1.93
Role of surgery in the treatment of primary carcinoma of the liver: a 31-year experience. Br J Surg (1987) 1.93
Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med (1999) 1.92
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol (2013) 1.92
von Recklinghausen's disease and pheochromocytomas. J Urol (1999) 1.92